Financials
Financial year 2025
EB Pharma Developments from Alken, company number BE0780755671, closed financial year 2025 with a result of € -1,347 after tax. For that financial year EB Pharma Developments recorded a gross margin of € -1,127 and equity of € 5,298. Compared with financial year 2024, the result moved from € 3,567 to € -1,347. The company made a loss. The buffer shrank hard: equity is 68 % below last year. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on March 25, 2026.
€ 5,298
▼ 68% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1,347
▼ still € 3,567 profit in 2024
Profit after tax over the fiscal year.
€ 8,736
▼ 9% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 3,798.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 636
▼ 67% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 20,964 | € -4,297 | € 3,749 | € -1,127 | ▼ € 4,876 |
| Profit after taxes | € 16,222 | € -4,644 | € 3,567 | € -1,347 | ▼ € 4,913 |
| Equity | € 17,722 | € 13,078 | € 16,645 | € 5,298 | ▼ 68% |
| Total debts | € 4,316 | € 0 | € 2,420 | € 11,654 | ▲ € 9,234 |
| Cash | € 12,482 | € 4,700 | € 9,619 | € 8,736 | ▼ 9% |
| Retained profit | € 16,222 | € 11,578 | € 15,145 | € 3,798 | ▼ 75% |
| Dividend | € 0 | € 0 | € 0 | € 10,000 | |
| Balance sheet total | € 22,037 | € 13,078 | € 19,064 | € 16,951 | ▼ 11% |
Key figures of EB Pharma Developments, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EB Pharma Developments?
What happened at EB Pharma Developments in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1,347 (▼ € 4,913 vs 2024). Source: NBB ↗
- New establishment in Alken. KBO
- Start of the company according to the CBE. KBO
- ERIK BUNTINX became a director. NBB
In short
From € 16,222 profit in 2022 to € 1,347 loss in 2025.
Paid € 4,316 in corporate taxes since 2022.
Best year ever: 2022, with € 16,222 profit.
Paid out € 10,000 in dividends to the owners in total.
A new publication or filing at EB Pharma Developments? We notify you, reason included.
Follow EB Pharma DevelopmentsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind EB Pharma Developments is ERIK BUNTINX. ERIK BUNTINX is also behind B & B BEHEER, ANIMA, INTEGRA INVEST Alken, Elise Buntinx and LINDE BUNTINX.
Directors
According to the 2025 annual accounts
ERIK BUNTINX
Director
Also active at: B & B BEHEER, ANIMA, INTEGRA INVEST Alken, Elise Buntinx, LINDE BUNTINX, Anima Medical
since 2022
Establishments
Establishment units
Physical locations of this company
Alkerstraat 28
3570 Alken
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Domain
Domain
animaresearch.com
Registered
2019-01-11
Registrar
Realtime Register B.V.
Expires
2027-01-11
Website info
Features
Security
Details
- Company number
- 0780.755.671
- VAT number
- BE 0780.755.671
- Registered office
- Alkerstraat 28, 3570 Alken
- Names & denominations
- EB Pharma Developments
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 21 January 2022
- Peppol
- Active · Active since 23 Apr 2026
- Contact
- animaresearch.com
- Activities · NACE
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied